Seeking adults aged 18 to 65 years with a clinical diagnosis of atopic dermatitis (AD), with AD-involved body surface area (BSA) ≥ 10% at
(roughly the size of 10 palm prints or more).Inclusion criteria include having moderate to severe AD for at least 6 months prior and a history of
inadequate response to treatment for AD with topical medications.
Participants will receive either treatment via a subcutaneous injection (SC) or placebo Study treatment and study-related assessments will be
provided at no cost. Reimbursement for study-related expenses may be provided.
Study participation will last about 7-8 months and involve about 12 visits to the study centre.
Mason - Dermatologists of Southwest Ohio
Las Vegas - Vivida Dermatology
Richmond Hill - The Centre for Dermatology
North Bay - North Bay Dermatology Centre
London - DermEffects
Etobicoke - Kingsway Clinical Research
Surrey - Enverus Medical Research
Similar Trials
No Similar Trials FoundThe following information is from ClinicalTrials.gov
Last Update Posted: December 10, 2023
NCT05935085
AnaptysBio, Inc.
Brief Summary:
This study will evaluate the safety, tolerability, and efficacy of ANB032 in subjects with moderate to severe atopic dermatitis (AD).
Condition or Disease:
Atopic Dermatitis Eczema
Intervention/Treatment:
Drug: ANB032Phase:
Phase 2
Ages Eligible for Study:
18 Years and 65 Years (Adult)
Sexes Eligible for Study:
All
Key Inclusion Criteria:
Male or female aged 18 to 65 years and in good general health
Moderate to severe AD for at least 6 months prior to Randomization
History of inadequate response to treatment for AD with topical medications or for whom topical treatments are otherwise medically inadvisable
EASI score ≥ 16 at Screening and at Randomization
vIGA AD score ≥ 3 at Screening and at Randomization
AD involved BSA ≥ 10% at Screening and at Randomization
Key Exclusion Criteria:
Any factors that in the Investigator’s opinion would predispose the subject to develop an infection
Known or suspected congenital or acquired immunodeficiency state, or condition that would compromise the subject’s immune status
Not able to tolerate SC drug administration
Tanning booth use or extended sun exposure that could affect disease severity or interfere with disease assessments within 4 weeks before Randomization
Terms and Conditions – ClinicalTrials.gov
Purpose of ClinicalTrials.gov Database. The U.S. National Institutes of Health, Department of Health and Human Services, through its National Library of Medicine, has developed ClinicalTrials.gov to provide patients, family members, and members of the public current information about clinical research studies.
register now